Vivani Medical (NASDAQ:VANI) Director Gregg Williams Purchases 1,587,301 Shares

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams acquired 1,587,301 shares of the business’s stock in a transaction on Wednesday, April 15th. The shares were bought at an average cost of $1.26 per share, with a total value of $1,999,999.26. Following the completion of the acquisition, the director owned 32,944,484 shares of the company’s stock, valued at approximately $41,510,049.84. This trade represents a 5.06% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Gregg Williams also recently made the following trade(s):

• On Sunday, March 15th, Gregg Williams bought 1,575,231 shares of Vivani Medical stock. The stock was acquired at an average price of $1.07 per share, with a total value of $1,685,497.17.
• On Tuesday, January 27th, Gregg Williams bought 1,351,351 shares of Vivani Medical stock. The stock was acquired at an average price of $1.48 per share, with a total value of $1,999,999.48.

Vivani Medical Stock Up 14.9%

Shares of VANI stock opened at $1.31 on Friday. The stock has a 50-day moving average price of $1.16 and a 200 day moving average price of $1.33. The firm has a market cap of $110.89 million, a price-to-earnings ratio of -3.05 and a beta of 2.16. Vivani Medical, Inc. has a 12 month low of $0.92 and a 12 month high of $1.92.

Vivani Medical (NASDAQ:VANI) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. Sell-side analysts predict that Vivani Medical, Inc. will post -0.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

VANI has been the subject of several research analyst reports. HC Wainwright decreased their price objective on Vivani Medical from $4.00 to $3.50 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vivani Medical in a research report on Friday, January 9th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $3.50.

Hedge Funds Weigh In On Vivani Medical

Several institutional investors and hedge funds have recently modified their holdings of the business. Tudor Investment Corp ET AL bought a new stake in Vivani Medical in the 4th quarter valued at approximately $1,127,000. Marshall Wace LLP bought a new stake in Vivani Medical in the 4th quarter valued at approximately $174,000. Geode Capital Management LLC lifted its stake in Vivani Medical by 29.6% in the 4th quarter. Geode Capital Management LLC now owns 461,652 shares of the company’s stock valued at $568,000 after acquiring an additional 105,398 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Vivani Medical by 118.4% in the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock valued at $121,000 after acquiring an additional 53,127 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in Vivani Medical in the 4th quarter valued at approximately $60,000. 6.78% of the stock is currently owned by institutional investors and hedge funds.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.